Targeted agents and systemic therapy in hepatocellular carcinoma Journal Article


Authors: Ang, C.; O'Reilly, E. M.; Abou-Alfa, G. K.
Article Title: Targeted agents and systemic therapy in hepatocellular carcinoma
Abstract: Cytotoxic chemotherapy, hormonal agents, and immunotherapy have been tested in hepatocellular cancer (HCC) with marginal efficacy to date. Recent insights into the molecular pathogenesis of HCC have identified several aberrant signaling pathways that have served as targets for novel therapeutic agents. These discoveries have been translated into the clinical realm with the use of the antiangiogenic and the Raf kinase inhibitor, sorafenib, and have revealed the potential of targeted agents to produce clinically meaningful survival benefits in patients with advanced HCC. Efforts continue in the quest to improve the outcome of HCC patients through the development and evaluation of other targeted agents, and to better understand the interactions between the underlying disease biology and response to therapy. Several pathways are now implicated in hepatocarcinogenesis and agents that target these pathways continue to be developed. © 2013 Springer-Verlag Berlin Heidelberg.
Journal Title: Recent Results in Cancer Research
Volume: 190
ISSN: 0080-0015
Publisher: Springer Verlag  
Date Published: 2013-01-01
Start Page: 225
End Page: 246
Language: English
DOI: 10.1007/978-3-642-16037-0_15
PROVIDER: scopus
PUBMED: 22941024
DOI/URL:
Notes: Book Chapter in "Multidisciplinary Treatment of Hepatocellular Carcinoma" (ISBN: 978-3-642-16036-3) (Online SBN: 978-3-642-16037-0) -- "Export Date: 3 December 2012" -- "CODEN: RRCRB" -- "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Ghassan Abou-Alfa
    568 Abou-Alfa
  2. Celina Su-Ping Ang
    33 Ang
  3. Eileen O'Reilly
    780 O'Reilly